Robert Ghenchev

Verana Health is a digital health company that delivers quality drug lifecycle, medical practice, and medical society insights from an exclusive real-world data network of more than 20,000 healthcare providers. Our specialty medical society partners entrust us to manage data from this network─nearly a half-billion, de-identified healthcare encounters─feeding it through our population health data engine, VeraQ™, to produce quality, disease-specific data sets, Qdata™. VeraQ and Qdata power the data analytics Verana Health conducts for Life Sciences–including for the top 4 of 5 pharmaceutical companies–and certain value-added services we offer healthcare providers in our network, such as MIPS quality reporting.

MightyOwl is an online educational platform that is looking to revolutionize the way students learn outside the classroom. Our short videos and educational materials make learning fun and exciting for students from K-8, and empower educators and parents to understand their educational journey.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

Verana Health is a digital health company that delivers quality drug lifecycle, medical practice, and medical society insights from an exclusive real-world data network of more than 20,000 healthcare providers. Our specialty medical society partners entrust us to manage data from this network─nearly a half-billion, de-identified healthcare encounters─feeding it through our population health data engine, VeraQ™, to produce quality, disease-specific data sets, Qdata™. VeraQ and Qdata power the data analytics Verana Health conducts for Life Sciences–including for the top 4 of 5 pharmaceutical companies–and certain value-added services we offer healthcare providers in our network, such as MIPS quality reporting.

Quanta Dialysis Technologies is committed to making dialysis accessible to every patient in every setting with its SC+ hemodialysis system. As a portable device with performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. With a simple-to-use and intuitive user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients. Disclaimer: The SC+ Haemodialysis system is FDA-cleared for use on patients with acute and/or chronic renal failure when administered by a trained person in an acute or chronic care facility. It is not indicated for home or nocturnal use in the USA. CONTACT US Office / Business Enquiries: UK: 0-178-940-0043 US: 1-978-483-0669 Customer Care: UK: 0-808-164-2640 US: 1-800-590-1393

MightyOwl is an online educational platform that is looking to revolutionize the way students learn outside the classroom. Our short videos and educational materials make learning fun and exciting for students from K-8, and empower educators and parents to understand their educational journey.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.